Accurate proteome-wide missense variant effect prediction with AlphaMissense
By Jun Cheng, Guido Novati, Joshua Pan, Clare Bycroft, Akvile Zemgulyte, Taylor Applebaum, Alexander Pritzel, L. H. Wong, Michal Zielinski, Tobias John Sargeant and 6 more. Science, 2023
1,696 citations recorded by the source corpus.
The vast majority of missense variants observed in the human genome are of unknown clinical significance. We present AlphaMissense, an adaptation of AlphaFold fine-tuned on human and primate variant population frequency databases to predict missense variant pathogenicity. By combining structural context and evolutionary conservation, our model achieves state-of-the-art results across a wide range of genetic and experimental benchmarks, all without explicitly training on such data. The average pathogenicity score of genes is also predictive for their cell essentiality, capable of identifying short essential genes that existing statistical approaches are underpowered to detect. As a resource to the community, we provide a database of predictions for all possible human single amino acid substitutions and classify 89% of missense variants as either likely benign or likely pathogenic. Description Editor’s summary Single–amino acid changes in proteins sometimes have little effect but can often lead to problems in protein folding, activity, or stability. Only a small fraction of variants have been experimentally investigated, but there are vast amounts of biological sequence data that are suitable for use as training data for machine learning approaches. Cheng et al. developed AlphaMissense, a deep learning model that builds on the protein structure prediction tool AlphaFold2 (see the Perspective by Marsh and Teichmann). The model is trained on population frequency data and uses sequence and predicted structural context, all of which contribute to its performance. The authors evaluated the model against related methods using clinical databases not included in the training and demonstrated agreement with multiplexed assays of variant effect. Predictions for all single–amino acid substitutions in the human proteome are provided as a community resource. —Michael A. Funk AlphaFold fine-tuned on human and primate population variant frequency databases predicts variant pathogenicity. INTRODUCTION Genome sequencing has revealed extensive genetic variation in human populations. Missense variants are genetic variants that alter the amino acid sequence of proteins. Pathogenic missense variants disrupt protein function and reduce organismal fitness, while benign missense variants have limited effect. RATIONALE Classifying these variants is an important ongoing challenge in human genetics. Of more than 4 million observed missense variants, only an estimated 2% have been clinically classified as pathogenic or benign, while the vast majority of them are of unknown clinical significance. This limits the diagnosis of rare diseases, as well as the development or application of clinical treatments that target the underlying genetic cause. Machine learning approaches could close the variant interpretation gap by exploiting patterns in biological data to predict the pathogenicity of unannotated variants. Specifically, AlphaFold, which accurately predicts protein structure from protein sequence, may be used as a foundation to predict the pathogenicity of variants on proteins. RESULTS We developed AlphaMissense to leverage advances on multiple fronts: (i) unsupervised protein language modeling to learn amino acid distributions conditioned on sequence context; (ii) incorporating structural context by using an AlphaFold-derived system; and (iii) fine-tuning on weak labels from population frequency data, thereby avoiding bias from human-curated annotations. AlphaMissense achieves state-of-the-art missense pathogenicity predictions in clinical annotation, de novo disease variants, and experimental assay benchmarks without explicitly training on such data. As a resource to the community, we provide a database of predictions for all possible single amino acid substitutions in the human proteome. We classify 32% of all missense variants as likely pathogenic and 57% as likely benign using a cutoff yielding 90% precision on the ClinVar dataset, thereby providing a confident prediction for most human missense variants. We show how this resource can be used to accelerate research in multiple fields. Molecular biologists could use the database as a starting point for designing and interpreting experiments that probe saturating amino acid substitutions across the human proteome. Human geneticists could combine gene-level AlphaMissense predictions with population cohort–based approaches to quantify the functional significance of genes, especially for shorter human genes where cohort-based approaches lack statistical power. Finally, clinicians could benefit from the boost in coverage of confidently classified pathogenic variants when prioritizing de novo variants for rare disease diagnostics, and AlphaMissense predictions could inform studies of complex trait genetics that use annotations of rare, likely deleterious variants. CONCLUSION AlphaMissense predictions may illuminate the molecular effects of variants on protein function, contribute to the identification of pathogenic missense mutations and previously unknown disease-causing genes, and increase the diagnostic yield of rare genetic diseases. AlphaMissense will also foster further development of specialized protein variant effect predictors from structure prediction models. AlphaMissense pathogenicity prediction. AlphaMissense takes as input a missense variant and predicts its pathogenicity. We fine-tuned AlphaFold on human and primate variant population frequency data and calibrated the confidence on known disease variants. AlphaMissense predicts the probability of a missense variant being pathogenic and classifies it as either likely benign, likely pathogenic, or uncertain. We provide predictions for all possible human missense variants as a resource for the community.
Subfields: Genetics
View Paper: https://www.semanticscholar.org/paper/a82137965925d7712dfb720e1f2ad39251d799eb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Guanming Wu
- M. Gillespie
- L. Matthews
- R. Haw
- B. Jassal
- Marija Milacic
- Ralf Stephan
- Bruce May
Citations in the corpus
- The Reactome Pathway Knowledgebase 2024 (2023, methodology): “…a clinical investigator with a novel variant that can be classified based on the appropriate catalog, or perhaps by a computational tool such as Al-phaMissense ( 16 ), to use Reactome to form specific, testable hypotheses for its likely effects at a pathway level and its drug susceptibility.”